FierceBiotechOriginal article
{"a":[{"_":"GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’","$":{"href":"/biotech/gsk-sees-phase-3-win-hansoh-partnered-adc-china-justifying-hype","hreflang":"en"}}]}
Phase 3positiveADCPositive
AI Analysis
Summary
Hansoh Pharmaceutical's Phase 3 ADC program achieved positive results in China, validating GSK's decision to designate it as a priority asset in their partnership.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 win for Hansoh-partnered ADC in China
Importance:7/10
Sentiment:
0.70
ADCChinapartnershipclinical trial
Read the original article
Published by FierceBiotech on July 10, 2026 8:17 AM